Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease (HORIZON PLUS)

This study has been completed.
Information provided by:
Medivation, Inc. Identifier:
First received: March 10, 2010
Last updated: March 5, 2012
Last verified: March 2012
An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.

Condition Intervention Phase
Huntington Disease
Drug: Dimebon (latrepirdine)
Phase 3

Study Type: Interventional
Official Title: HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

Resource links provided by NLM:

Further study details as provided by Medivation, Inc.:

Arms Assigned Interventions
Experimental: Dimebon (latrepirdine) Drug: Dimebon (latrepirdine)


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Successful completion of 26 weeks of blinded treatment in the HORIZON study

Exclusion Criteria:

  • Any other medical illness or unstable medical condition that may interfere with their ability to comply with study procedures and abide by study restrictions, or may interfere with the ability to interpret safety information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information Identifier: NCT01085266     History of Changes
Other Study ID Numbers: DIM20EXT 
Study First Received: March 10, 2010
Last Updated: March 5, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Neurocognitive Disorders
Mental Disorders processed this record on September 28, 2016